Clinical trials: Cardiovascular Outcomes
AORTIC VALVE DISEASES, Aortic Valve Stenosis and Insufficiency
Post-market Safety and Performance Outcomes of the VIVERE® Bovine Pericardial Bioprosthetic Valve
This study aims to collect post-market safety and performance data related to the procedure and follow-up of the VIVERE Bovine Pericardial Bioprosthetic Valve, when used in accordance with the product's Instructions for Use (IFU).
- Conditions
- AORTIC VALVE DISEASES, Aortic Valve Stenosis and Insufficiency, Aortic Valve Surgery, Mitral Valve Regurgitation
- Trial name
- VITTA (NCT06959836)
- Testing
- VIVERE Bovine Pericardial Bioprosthetic Valve
- Where
- 3 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- Braile Biomedica Ind. Com. e Repr. Ltda.
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi
Deep Vein Thrombosis Leg, DVT
ClotTriever Outcomes (CLOUT) Registry
Evaluate real world patient outcomes after treatment of acute, subacute, and chronic proximal lower extremity deep vein thrombosis (DVT) with the ClotTriever Thrombectomy System.
- Conditions
- Deep Vein Thrombosis Leg, DVT, Chronic DVT of Lower Extremity, Acute DVT of Lower Extremity
- Trial name
- CLOUT (NCT03575364)
- Testing
- ClotTriever
- Where
- 43 sites in United States
- Volunteers
- 499 people
- Sponsor
- Inari Medical
Non-valvular Atrial Fibrillation (NVAF)
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
This is an observational study in which data collected from the past of patients with non-valvular atrial fibrillation (NVAF) is studied.
- Trial name
- RENOVATOR (NCT05022758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- South Korea
- Volunteers
- 45,000 people
- Sponsor
- Bayer
Heart Failure
A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)
A study of participants hospitalized with acute heart failure with reduced ejection fraction
- Trial name
- NCT03515655
- Where
- United States
- Volunteers
- 99,209 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and…
- Trial name
- NCT02465515
- Testing
- Albiglutide 30 mg, Albiglutide 50 mg
- Where
- 607 sites in United States, Argentina and 26 more
- Volunteers
- 9,463 people
- Sponsor
- GlaxoSmithKline
Stroke, Brachial Plexus Injury
Retrospective Study on Myoelectric Elbow-Wrist-Hand Orthosis User Outcomes
The objective of this study is to retrospectively evaluate the outcomes and clinical benefits provided by this brace to adult patients with upper limb impairment or paralysis due to brachial plexus, stroke (CVA), spinal cord…
- Conditions
- Stroke, Brachial Plexus Injury, Spinal Cord Injuries, Neurological Disease
- Trial name
- NCT05575674
- Testing
- Myoelectric Elbow-Wrist-Hand Orthosis
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Myomo
Atherosclerotic Cardiovascular Disease
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Spain)
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke.
- Trial name
- NCT07905534
- Where
- Spain
- Volunteers
- 18,000 people
- Sponsor
- Sanofi
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
The objective of this study is to collect safety and effectiveness data on the Penumbra System reperfusion catheters in participants with isolated primary non-dominant and distal M2 occlusions who undergo endovascular mechanical…
- Trial name
- NCT07749170
- Testing
- Endovascular Thrombectomy, Medical Management
- Where
- 7 sites in United States
- Volunteers
- 250 people
- Sponsor
- Penumbra Inc.
Acute Coronary Syndrome
MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial
This study will be a proof-of-concept, placebo-controlled, double-blind, randomized trial in participants with a recent acute coronary syndrome (ACS) to evaluate the efficacy, pharmacokinetics, safety, tolerability, disease…
- Trial name
- PILOT (NCT02678923)
- Testing
- MDCO-216
- Where
- 20 sites in Canada, Czechia and 3 more
- Volunteers
- 126 people
- Sponsor
- The Medicines Company
Myocarditis
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.
- Trial name
- NCT06189053
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- ModernaTX, Inc.
Obstructive Hypertrophic Cardiomyopathy
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
This registry evaluates patient characteristics, real-world treatment patterns, and short- and long-term outcomes in a population of patients in the United States and Europe with symptomatic obstructive hypertrophic…
- Trial name
- DISCOVER-HCM (NCT05489705)
- Testing
- Mavacamten, Non-mavacamten symptomatic oHCM therapy
- Where
- 101 sites in United States, Austria and 7 more
- Volunteers
- 1,700 people
- Sponsor
- Bristol-Myers Squibb
Hyperkalemia
Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes in participants on chronic hemodialysis with recurrent hyperkalemia.
- Trial name
- NCT04847232
- Testing
- Sodium Zirconium Cyclosilicate (SZC)
- Where
- 340 sites in United States, Argentina and 24 more
- Volunteers
- 2,690 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases
A Study of Evacetrapib in High-Risk Vascular Disease
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
- Trial name
- ACCELERATE (NCT01687998)
- Testing
- Evacetrapib
- Where
- 444 sites in United States, Argentina and 35 more
- Volunteers
- 12,092 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Diseases
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective…
- Trial name
- NCT00153101
- Testing
- Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
- Where
- 732 sites in United States, Argentina and 39 more
- Volunteers
- 31,546 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)
The aim of this Post Authorisation Safety Study (PASS) is to assess the incidence of adverse cardiovascular and cerebrovascular events in COPD patients who are new to inhaled fixed triple therapy (dual bronchodilator plus…
- Trial name
- TRIBE (NCT05652439)
- Testing
- Observational retrospective data collection
- Where
- United Kingdom
- Volunteers
- 25,000 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the…
- Trial name
- CLEOPATTRA (NCT07207811)
- Testing
- NNC6019-0001
- Where
- 299 sites in United States, Argentina and 18 more
- Volunteers
- 1,280 people
- Sponsor
- Novo Nordisk A/S
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Acute Coronary Syndromes
An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index…
- Trial name
- TARGET (NCT01061086)
- Where
- 11 sites in Greece
- Volunteers
- 418 people
- Sponsor
- AstraZeneca
Heart Failure
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
This study was to determine early and more chronic changes in concentrations of biomarkers related to mechanisms of action (MOA) and effects of sacubitril/valsartan therapy over a period of 12 months, and correlated these…
- Trial name
- PROVE-HF (NCT02887183)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 77 sites in United States
- Volunteers
- 794 people
- Sponsor
- Novartis Pharmaceuticals